Clinical Trial Update: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) [Phase 1]

View source ↗

Summary

Phase I, open-label multicenter trial evaluating safety, tolerability, and pharmacokinetics of selumetinib (AZD6244) in cancer patients; current status is Activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colon Cancer
• Kidney Cancer
• Lung Cancer
• Melanoma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer, Breast Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING